top of page
Biotech Files
4 specialty pharmaceutical stocks could be the next takeover candidates
by Lee Jackson, 247wallst.com
Zacks' Jason Napodano is not focused on a biotech bubble
By George S. Mack of The Life Sciences Report,
talkmarkets.com
Conatus: Emricasan's 4 indications present a lucrative opportunity in the liver disease market
by Pistachio Investments, seekingalpha.com
Mast Therapeutics: Why Is The Stock Lagging Despite A Decent Drug?
by Kanak Kanti De, seekingalpha.com
Cantor Fitzgerald's Caroline Corner: Cutting-edge devices and diagnostics deliver drugs and profits
by George S. Mack, 247wallst.com
Subscribe to Biotech Gems, a premium investment newsletter covering biotech and biopharma stock sectors of the stock market. Click here to learn more.
Biotech Revolution: 3 Stocks Under $5 with Triple Digit Potential for the Remainder of 2015. Click here to get your Free Report.
The $4Bn Patient: Will Dynavax's Study Finally Remove Safety Doubts From Heplisav?
by Sirius Capital, seekingalpha.com
Does Celgene's Success With Otezla Strengthen The Investment Case For Can-Fite BioPharma?
by Jason Napodano, CFA, bionapinc.com
Esperion Therapeutics Inc (ESPR) Jumps Then Slumps after ETC-1002 Update; Are Hedge Funds Bullish on the Stock?
By Solon Harmony B. Dolor, insidermonkey.com
Deerfield Management Discloses 3.66% Stake In Newly Public Company Global Blood Therapeutics Inc. (GBT)
by Gene Guzun, insidermonkey.com
bottom of page